Is ZOMDF a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Zomedica (ZOMDF) rests on PulseVet consumables and the installed base: Therapeutic Devices produced ~$7.2 million of third-quarter 2026 revenue, about 73% of the total, at a ~64% segment gross margin. The bear case rests on the plainest risk is that Zomedica still loses money: ~$16 million of net loss over the trailing twelve months on Yahoo's figures, a period with no impairment charges, and it has never reported a profitable year. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

ZOMDF key stats

At $0.08 on November 20, 2026, Zomedica (ZOMDF) has a market cap of $78M.

Market cap
$78M
Price to book
0.8
Beta
1.32

Market cap, P/E and yield are measured at the $0.08 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Zomedica (ZOMDF)?

The last two weeks for Zomedica, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.

  • ZOMDF closed at $0.08 on November 20, 2026, down 18.4% over the past five trading days (from $0.10).

Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Zomedica Corp. is an Alberta-incorporated, Michigan-based animal-health company that sells therapeutic devices and point-of-care diagnostics to equine and companion-animal veterinarians. Its largest line is the PulseVet electrohydraulic shockwave system, acquired in 2021, which treats tendon, ligament, bone and wound conditions and earns recurring revenue from replacement applicators called trodes. It also sells Assisi pulsed electromagnetic devices, VETIGEL hemostatic gel, the TRUFORMA diagnostic platform, VETGuardian remote vital-signs monitoring and TRUVIEW digital cytology. A third segment, Development Services, began in the second half of 2025 and sells engineering, development and contract manufacturing work to outside partners. In September 2026 it announced a strategic partnership with Veterinary Study Groups (VMG) to bring its technologies to independent practices. The business is small but no longer tiny. Revenue was ~$32.0 million in 2025, including a record ~$10.5 million fourth quarter, and ~$28.2 million in the first nine months of 2026, up ~31%. Third-quarter 2026 revenue, reported November 4, was a third-quarter record of ~$9.9 million, up ~22% from ~$8.1 million, with Therapeutic Devices at ~$7.2 million (up ~7%), Diagnostics at ~$1.6 million (up ~113%) and Development Services at ~$1.1 million. Excluding Development Services, revenue grew ~18%. Consumables rose ~26% to ~$6.8 million. Gross margin ran ~61% in the quarter, and operating expenses fell ~21% to ~$9.5 million. The company still lost ~$3.2 million in the quarter, down from ~$6.1 million a year earlier, and ~$11.5 million over nine months. In 2025 it booked ~$55.8 million of non-cash impairment charges, writing off all goodwill on PulseVet and Assisi after its share price fell. The stock's history explains much of its current price. Zomedica raised large sums during the 2021 retail trading wave and ended up with ~980 million common shares outstanding. NYSE American suspended trading on March 4, 2025, under its rule on shares trading at abnormally low prices, and the shares moved to the OTCQB as ZOMDF the next day. The company still files 10-Ks and 10-Qs with the SEC. At ~$0.08, the market value is roughly ~$80 million against ~$40.9 million of cash and available-for-sale securities at September 30, 2026, and Yahoo puts the shares at about 0.77 times book value. Management's second-quarter 10-Q said existing cash was sufficient for the next 12 months and beyond and reported no pending legal proceedings, and the third-quarter release said the company is well positioned to close the year strong without giving numerical guidance.

The bull case for ZOMDF

1. PulseVet consumables and the installed base

Therapeutic Devices produced ~$7.2 million of third-quarter 2026 revenue, about 73% of the total, at a ~64% segment gross margin. The model resembles a razor-and-blade business: each PulseVet system sold adds a clinic that buys replacement trodes, and consumables revenue rose ~26% to ~$6.8 million in the quarter while capital sales of PulseVet and VETGuardian systems came to ~$2.0 million. PulseVet began in equine sports medicine and has been extended to small animals through the X-trode handpiece. How many new systems are placed each quarter, and how heavily existing clinics use them, largely determines whether this segment keeps growing faster than the ~7% it managed in the third quarter.

2. TRUFORMA diagnostics and the Boehringer collaboration

Diagnostics revenue was ~$1.6 million in the third quarter of 2026, up ~113%, after ~$1.4 million in the second quarter (up ~77%). TRUFORMA is a bulk acoustic wave sensor platform for in-clinic tests, including equine assays, and Zomedica bought the sensor maker's biotechnology unit from Qorvo in 2023 to control its supply. Management credits a commercial collaboration with Boehringer Ingelheim Animal Health and new international distributors for the acceleration. The segment is still small next to the incumbents in veterinary diagnostics, so growth from a ~$5-6 million annual base can look large in percentage terms while staying modest in dollars.

3. Development Services as a new revenue line

Development Services, launched in the second half of 2025, sells Zomedica's engineering, development and manufacturing capacity to partners in both animal and human health. It produced ~$3.1 million in 2025, ~$3.4 million in the first half of 2026 and ~$1.1 million in the third quarter, a step down from ~$1.4 million in the second, and it explains the gap between ~22% reported growth and ~18% growth in the core product lines. This revenue uses capacity the company already pays for, which helps operating leverage, but it is project-based. Contract work can arrive in lumps and end when a program finishes, so it may prove less predictable than trode reorders.

4. Cost cuts and the path toward breakeven

Operating expenses fell ~21% to ~$9.5 million in the third quarter of 2026, after a ~20% drop to ~$10.1 million in the second. Quarterly cash burn dropped to ~$3.2 million, down ~32% from a year earlier, after ~$18.1 million of burn for all of 2025. The third-quarter net loss narrowed to ~$3.2 million from ~$6.1 million a year earlier, and adjusted EBITDA loss to ~$1.6 million from ~$3.9 million. With ~$40.9 million of liquidity, burn at the current pace would leave several years of runway. Management describes cash-flow breakeven as its stated goal; it has not yet reported a profitable quarter.

The bear case for ZOMDF

The plainest risk is that Zomedica still loses money: ~$16 million of net loss over the trailing twelve months on Yahoo's figures, a period with no impairment charges, and it has never reported a profitable year. Cash and securities fell to ~$40.9 million at September 30, 2026 from ~$44.1 million in June as the company funded losses, and a slower burn reduction would shorten its runway. The share count is very large at ~980 million, so even small per-share price moves change the market value meaningfully, and any future equity raise at today's prices would dilute heavily. OTCQB trading usually means thinner liquidity, wider spreads and less analyst coverage than an exchange listing; no analysts publish estimates on Yahoo. Shareholders rejected the executive pay proposal at the June 2026 meeting, a sign of investor frustration, and the stock is down about 26% over the year to November 20, 2026. Commercially, PulseVet faces other shockwave and rehabilitation devices, TRUFORMA competes with much larger diagnostic suppliers, and Development Services revenue depends on a few project contracts and already dipped quarter over quarter. Finally, the 2025 impairments show that past acquisitions have not earned back what was paid for them.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ZOMDF already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on ZOMDF

Too few analysts publish on ZOMDF for a consensus target to mean anything, so there is no professional average to weigh against your own view. That cuts both ways: less informed opinion to lean on, and less of it already priced in. The ZOMDF forecast page covers what coverage does exist.

How is ZOMDF valued?

Market cap, P/E and dividend yield at today's price are in the ZOMDF key stats above. The business figures below come from Zomedica's reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$38.7 million; Q3 2026 ~$9.9 million, up ~22%
  • Net loss (TTM): ~$16 million; Q3 2026 ~$3.2 million (vs ~$6.1 million)
  • Gross margin (Q3 2026): ~61%
  • Cash + securities (Sep 30, 2026): ~$40.9 million
  • Shares outstanding: ~980 million

As of November 2026: Trailing revenue is derived from ~$32.0 million in 2025 plus ~$28.2 million in the first nine months of 2026, less ~$21.6 million in the first nine months of 2025. At ~$0.08 a share, the market value of ~$80 million is about ~2.1 times sales and below book value (Yahoo shows ~0.77 times book). Subtracting ~$40.9 million of liquidity leaves an enterprise value near ~$39 million, about ~1.0 times sales. Because the company is unprofitable, earnings-based multiples do not apply.

How do you decide if ZOMDF is a buy?

Whether ZOMDF is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold ZOMDF indirectly through an index or sector ETF before adding more.

What would change your mind on ZOMDF

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: PulseVet consumables and the installed base stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: the plainest risk is that Zomedica still loses money: ~$16 million of net loss over the trailing twelve months on Yahoo's figures, a period with no impairment charges, and it has never reported a profitable year fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the ZOMDF stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ZOMDF against your real portfolio and see your actual exposure before deciding.

Your questions about Zomedica

Ask Walnut's AI anything about ZOMDF and see how it fits what you own.

FAQ

Is ZOMDF a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on PulseVet consumables and the installed base, with revenue (ttm) at ~$38.7 million; Q3 2026 ~$9.9 million, up ~22%. The bear case rests on the plainest risk is that Zomedica still loses money: ~$16 million of net loss over the trailing twelve months on Yahoo's figures, a period with no impairment charges, and it has never reported a profitable year. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell ZOMDF?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The plainest risk is that Zomedica still loses money: ~$16 million of net loss over the trailing twelve months on Yahoo's figures, a period with no impairment charges, and it has never reported a profitable year. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. Walnut is not an investment adviser.

What is the bull case for ZOMDF?

+

PulseVet consumables and the installed base. Therapeutic Devices produced ~$7.2 million of third-quarter 2026 revenue, about 73% of the total, at a ~64% segment gross margin.

What is the bear case for ZOMDF?

+

The plainest risk is that Zomedica still loses money: ~$16 million of net loss over the trailing twelve months on Yahoo's figures, a period with no impairment charges, and it has never reported a profitable year. Cash and securities fell to ~$40.9 million at September 30, 2026 from ~$44.1 million in June as the company funded losses, and a slower burn reduction would shorten its runway. The share count is very large at ~980 million, so even small per-share price moves change the market value meaningfully, and any future equity raise at today's prices would dilute heavily. OTCQB trading usually means thinner liquidity, wider spreads and less analyst coverage than an exchange listing; no analysts publish estimates on Yahoo. Shareholders rejected the executive pay proposal at the June 2026 meeting, a sign of investor frustration, and the stock is down about 26% over the year to November 20, 2026. Commercially, PulseVet faces other shockwave and rehabilitation devices, TRUFORMA competes with much larger diagnostic suppliers, and Development Services revenue depends on a few project contracts and already dipped quarter over quarter. Finally, the 2025 impairments show that past acquisitions have not earned back what was paid for them.

What does Zomedica do?

+

Animal-health device maker behind PulseVet shockwave systems and TRUFORMA diagnostics.

What would have to change for ZOMDF to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (PulseVet consumables and the installed base) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the plainest risk is that Zomedica still loses money: ~$16 million of net loss over the trailing twelve months on Yahoo's figures, a period with no impairment charges, and it has never reported a profitable year) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Zomedica do?

+

Zomedica sells therapeutic devices and point-of-care diagnostics to veterinarians who treat horses, dogs and cats. Its biggest product is the PulseVet shockwave system, which treats musculoskeletal injuries and wounds and generates repeat revenue from replacement applicators called trodes. It also sells Assisi pulsed electromagnetic devices, VETIGEL to stop bleeding, the TRUFORMA diagnostic testing platform, VETGuardian remote vital-signs monitoring and TRUVIEW digital cytology. Since the second half of 2025 it has also run a Development Services segment that sells engineering and contract manufacturing work to partners in animal and human health. The company is incorporated in Alberta, Canada, is headquartered in Ann Arbor, Michigan, and had ~141 employees at the end of 2025, according to its annual report.

Why is Zomedica traded as ZOMDF instead of ZOM?

+

Zomedica used to trade on NYSE American as ZOM. On March 4, 2025, NYSE American suspended trading and began delisting proceedings under its rule on shares that trade at abnormally low prices for an extended period, after the stock had spent a long time well below $1. The shares moved to the OTCQB Venture Market the next morning under the ticker ZOMDF, and in August 2025 the company registered its common shares under Section 12(g) so it remains an SEC reporting company. Zomedica said at the time that the move did not change its operations. It still files 10-K and 10-Q reports and holds annual meetings. Trading on the OTCQB typically comes with lower volume and wider bid-ask spreads than a national exchange.

How much revenue does Zomedica make?

+

Zomedica reported ~$32.0 million of revenue for 2025, up from the prior year, including a record ~$10.5 million in the fourth quarter. In 2026 it reported ~$8.8 million in the first quarter, ~$9.5 million in the second and ~$9.9 million in the third, for ~$28.2 million over nine months, up ~31%. That puts trailing twelve-month revenue at roughly ~$38.7 million. Third-quarter revenue split into ~$7.2 million from Therapeutic Devices, ~$1.6 million from Diagnostics and ~$1.1 million from Development Services. The company says core growth excluding Development Services was ~18% in the third quarter.

Walnut is informational, not investment advice, and gives no verdict on ZOMDF. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks